PPARγ is expressed in various tumour types, such as liposarcoma, human breast cancer, colon cancer, prostate cancer, and lung cancer, and it inhibits cell proliferation in human NSCLC, ovarian cancer, and pancreatic cancer via apoptosis.42–44 An increasing number of studies have reported the utility of PPARγ agonists as anti-cancer agents. Here, PPARG is linked to lung cancer.